This Monday, February 23, the French National Agency for the Safety of Medicines and Health Products (ANSM) published a press release announcing the recall of batches of oral Doliprane for babies and children (between 3 and 26 kg). At the origin of this procedure? A manufacturing defect on the dosing pipettes supplied with certain vials of Doliprane 2.4% oral suspension.
The ANSM has shared the list of recalled batches. If you have a drug in question, you should return the batch to the pharmacy.
Pediatric Doliprane recall: what are the risks?
The ANSM that the graduations of the pipettes of the recalled batches may gradually disappear when they are rinsed with warm or hot water. However, rinsing the pipette after each use is a usual hygiene gesture and recommended to parents. A pipette whose landmarks have disappeared then exposes to a dosing error, and therefore to a potential risk of paracetamol overdose in infants and young children.
The laboratory has thus recalled, in agreement with the ANSM, 27 batches distributed in city pharmacies between November 12, 2025 and February 3, 2026. The origin of the problem was located at a single production site and has since been corrected, and no anomalies were detected on the pipettes from the other sites. No adverse effects have been reported to date. The ANSM would like to make it clear: the quality of the drug itself is not in question.
